Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054880 · ClinicalTrials.gov registry record · Phase 4
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
A Phase 4 study of Ureter Injury, sponsored by Prove pharm.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT06054880 is a Phase 4 study of Ureter Injury that is actively recruiting participants, run by Prove pharm. The registered enrollment target is 116 participants, above the 92-participant average among 5 other Ureter Injury trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06054880, a Phase 4 study of Ureter Injury, is actively recruiting participants, sponsored by Prove pharm.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo when used as an aid in the determination of ureteral patency.
Conditions Studied
Interventions
- DRUG Indigotindisulfonate sodium 0.8%
- OTHER Saline injection 0.9%
Study Locations (1)
New York
- Albany Medical Center - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054880
The ClinicalTrials.gov registry entry for NCT06054880 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 5 other Ureter Injury trials with a reported enrollment target (26% higher). The listed sponsor is Prove pharm, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ureter Injury appearing as the primary indexed condition, and to 2 interventions - of which Indigotindisulfonate sodium 0.8% is the first listed.
NCT06054880 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06054880 about?
NCT06054880 is a clinical study titled "Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency". This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo when used as an aid in the determination of ureteral patency.
What is the current status of trial NCT06054880?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2023-10-12. Estimated completion is 2026-02-28.
What conditions does trial NCT06054880 study?
This clinical trial studies the following conditions: Ureter Injury.
What interventions are being tested in trial NCT06054880?
The interventions under investigation include: Indigotindisulfonate sodium 0.8% (DRUG), Saline injection 0.9% (OTHER).
Who is sponsoring clinical trial NCT06054880?
This trial is sponsored by Prove pharm, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06054880 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ureter Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
RECRUITING · Phase 4
-
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
RECRUITING · Phase 1
-
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
COMPLETED · Phase 3
-
A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy
COMPLETED · Phase 2
-
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.